Sarilumab, an FDA-approved anti-IL-6R antibody for rheumatoid arthritis, which blocks both mIL-6R and sIL-6R, is currently under clinical studies for breast cancer (144). The gene discussed is IL6R; the disease is rheumatoid arthritis.